Drug Safety
Drs. Jack Cush and Arthur Kavanaugh discuss highlights and key takeaways from ACR 23.
This included the following abstracts:
0025 Cannibinoids & pain
1584 TMP/SMX in GPA
0607 CAR-T cells in…
1 year ago
Large French study on infection risk of PsA biologics
12k pts over 6 years
When compared to Humira, only Enbrel and Stelara had lower infection risk
Concurrent steroid use associated with increased infection 1.85HR
@RheumNow #ACR23 Abs#2566 https://t.co/Os1esuodfl
1 year ago
L16 @ #ACR23
⭐️Can you discontinue glucocorticoids (GC) & immunosuppressive agent (IM) in stable IgG4-RD (clinically quiescent for at least 12 mo)?
➡️146 pts followed for 18 mo:
👉Group 1: withdraw GC+IM
vs
👉Group 2: withdraw GC… https://t.co/j77xYm9qSN https://t.co/72IwBeEwv9
1 year ago
Peng et al. 146 IgG4-RD in remission on immunomodulators+GC. 18 month follow-up. Withdraw IM+GC - 52% flare. Withdraw GC + continue IM 14.2% flare. Continue both 12.2% flare. Clear message that ongoing IM is the way Abstr#L16 #ACR23 #ACRbest @RheumNow https://t.co/3CAQhyTYqq https://t.co/qr1GOSvJYg
1 year ago
What happens when you stop #steroids and/ immunosuppressive Rx in Pts in remission for at least 1 yr in #IgG4 disease?
You are likely guessing correctly
Pts flare! Don’t stop Rx
?taper 🤷♀️
Like RA Rx - if stop Rx = flares
Large RCT from China L16 #ACR23 @RheumNow @RheumNow